Latest news with #TimBoreham
Mercury
10-07-2025
- Health
- Mercury
Health Kick Podcast: Neurizon Therapeutics
Stockhead's health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast. In this episode, Tim speaks with Neurizon Therapeutics (ASX:NUZ) managing director Dr Michael Thurn about the company's research on motor neurone disease and its drug development of NUZ-001 to treat ALS. NUZ-001 is developed from monepantel, a drug which originated in veterinary practise as a drench for the treatment and control of gastrointestinal roundworms in sheep. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles. Neurizon has now developed a liquid formulation of NUZ-001 to improve patient access and experience. Tune into the podcast to hear more. This podcast was developed in collaboration with Neurizon Therapeutics, a Stockhead advertiser at the time of publishing. The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions. Originally published as Health Kick Podcast: Neurizon's ALS push and trial plans
The Australian
10-07-2025
- Health
- The Australian
Health Kick Podcast: Neurizon Therapeutics
Stockhead's health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast. In this episode, Tim speaks with Neurizon Therapeutics (ASX:NUZ) managing director Dr Michael Thurn about the company's research on motor neurone disease and its drug development of NUZ-001 to treat ALS. NUZ-001 is developed from monepantel, a drug which originated in veterinary practise as a drench for the treatment and control of gastrointestinal roundworms in sheep. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles. Neurizon has now developed a liquid formulation of NUZ-001 to improve patient access and experience. Tune into the podcast to hear more. This podcast was developed in collaboration with Neurizon Therapeutics, a Stockhead advertiser at the time of publishing. The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions.
Mercury
08-07-2025
- Health
- Mercury
Health Kick Podcast: Filamon
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. Stockhead's health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast. In this episode, Tim speaks with Professor Paul de Souza, medical oncologist and co-founder of private drug developer Filamon, which is advancing a pipeline of anti-inflammatory therapies for cancer and chronic disease. The company's lead compound, a cyclic peptide with early signs of tolerability, is headed into a Phase 1b/2a adaptive trial, targeting multiple late-stage solid tumours by disrupting the tumour microenvironment. Filamon's founders bring decades of clinical and research experience, with a long-standing collaboration underpinning its scientific approach. And with a second fundraising round underway, the team is eyeing a future ASX listing. Tune into the podcast to hear more about Filamon's mission and what's next. This podcast was developed in collaboration with Filamon, a Stockhead advertiser at the time of publishing. The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions. Originally published as Health Kick Podcast: Filamon's bold push against cancer and chronic disease
